An Assessment of Five (PANSS, SAPS, SANS, NSA-16, CGI-SCH) commonly used Symptoms Rating Scales in Schizophrenia and Comparison to Newer Scales (CAINS, BNSS)

Suneeta Kumari, Mansoor Malik, Christina Florival, Partam Manalai, Snezana Sonje, Suneeta Kumari, Mansoor Malik, Christina Florival, Partam Manalai, Snezana Sonje

Abstract

Scales measuring positive and negative symptoms in schizophrenia remain the primary mo Scales measuring positive and negative symptoms in schizophrenia remain the primary mode of assessing and diagnosing schizophrenia by clinicians and researchers. The scales are mainly used to monitor the severity of positive and negative symptoms and track treatment response in schizophrenics. Although these scales are widely used, quality as well as general utility of each scale varies. The quality is determined by the validity and reliability of the scales. The utility of the scale is determined by the time of administration and the settings for which the scales can be administered in research or clinical settings. There are relatively fewer articles on the utility of newer scales like CAINS (Clinical Assessment Interview for Negative Symptoms) and the BNSS (Brief Negative Symptom Scale) that compare them to the older scales PANSS (Positive and Negative Symptoms Scale), SAPS (Scale for the Assessment of Positive Symptoms) SANS (the Scale for the Assessment of Negative Symptoms), NSA-16 (Negative Symptom Assessment-16) and CGI-SCH (Clinical Global Impression Schizophrenia. The older scales were developed more than 30 years ago. Since then, our understanding of negative symptoms has evolved and currently there are newer rating scales evaluating the validity of negative symptoms. The older scales do not incorporate the latest research on negative symptoms. CAINS and BNSS are attractive for both their reliability and their concise accessible format, however, a scale that is simpler, accessible, user-friendly, that incorporates a multidimensional model of schizophrenia, addresses the psychosocial and cognitive component has yet to be developed.

Keywords: Clinical practice; Mental health; Psychopathology; Schizophrenia.

References

    1. Crow TJ. Molecular pathology of schizophrenia: More than one disease process? Br Med J. 1980;280:66–68.
    1. Andresen NC, Flaum M, Arndt S, Alliger R, Swayze VW. Positive and negative symptoms: Assessment and validity. Negative vs Positive Schizophrenia. 1991:28–51.
    1. Crow TJ. The two-syndrome concept: Origins and current status. Schizophr Bull. 1985;11:471–486.
    1. Andresen NC. The scale for the assessment of positive symptoms. Iowa City: University of Iowa Press; 1984.
    1. Andresen NC. The scale for the assessment of positive symptoms. Iowa City: University of Iowa Press; 1985.
    1. Andresen NC, Flaum M, Arndt S, Alliger R, Swayze VW. Positive and negative symptoms: Assessment and validity. Negative versus positive schizophrenia. 1992:28–51.
    1. Johnstone EC, Owens DGC, Firth CD, Crow TJ. The relative stability of positive and negative features in chronic schizophrenia. Br J Psychiatry. 1986;150:60–64.
    1. Malia AK, Norman RM, Williamson P. Stability of positive and negative symptoms in schizophrenia. Can J Psychiatry. 1993;38:617–621.
    1. Klimidis S, Stuart GW, Minas IH, Copolov DL, Singh BS. Positive and negative symptoms in the psychoses. Re-analysis of published SAPS and SANS global ratings. Schizophr Res. 1993;9:11–18.
    1. Minas IH, Stuart GW, Klimidis S, Jackson HJ, Singh BS, et al. Positive and negative symptoms in the psychoses: Multidimensional scaling of SAPS and SANS items. Schizophr Res. 1992;8:143–156.
    1. Andreasen NC, Arndt S, Miller D, Flaum M, Nopoulos P. Correlational studies of the scale for the assessment of negative symptoms and the scale for the Assessment of positive symptoms: An overview and update. Psychopathology. 1995;28:7–17.
    1. Rabinowitz J, Harvey PD, Eerdekens M, Davidson M. Premorbid functioning and treatment response in recent-onset schizophrenia. Br J Psychiatry. 2006;189:31–35.
    1. Mortimer AM. Symptom rating scales and outcome in schizophrenia. Br J Psychiatry Suppl. 2007;50:S7–S14.
    1. Obermeier M, Schennach-Wolff R, Meyer S, Möller HJ, Riedel M, et al. Is the PANSS used correctly? A systematic review. BMC Psychiatry. 2011;11:113.
    1. Alphs LD, Summerfelt A, Lann H, Muller RJ. The negative symptom assessment: A new instrument to assess negative symptoms of schizophrenia. Psychopharmacol Bull. 1989;25:159–163.
    1. Axelrod BN, Goldman RS, Alphs LD. Validation of the 16-item negative symptom assessment. J Psychiatr Res. 1993;27:253–258.
    1. Velligan DI, Alphs L, Lancaster S, Morlock R, Mintz J. Association between changes on the negative symptom assessment scale (NSA-16) and measures of functional outcome in schizophrenia. Psychiatry Res. 2009;169:97–100.
    1. Kane JM. Tools to assess negative symptoms in schizophrenia 2013
    1. Portilla MPG, Alvarez LG, Saiz PA. Psychometric evaluation of the negative syndrome of schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2015;265:559–566.
    1. Alphs L, Morlock R, Coon C, Cazorl P, Szegedi A, et al. Validation of a 4-item negative symptom assessment (NSA-4): A short, practical clinical tool for the assessment of negative symptoms in schizophrenia. Int J Methods Psychiatr Res 2011
    1. Haro JM, Kamath SA, Ochoa S. The clinical global impression-schizophrenia scale: A simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl. 2003:16–23.
    1. Guy W. Clinical global impression In: ECDEU assessment manual for psychopharmacology (revised) Rockville, MD: National institute of mental health; 1976. pp. 217–221.
    1. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the clinical global impressions (CGI) scale for use in bipolar illness (BP): The CGI-BP. Psychiatry Res. 1997;73:159–171.
    1. Haro JM, Edgell ET, Jones PB, Alonso J, Gavart S. The European schizophrenia outpatient health outcome (SOHO) study: Rationale, methods and recruitment. Acta Psychiatr Scand. 2003;107:222–232.
    1. Kay SR, Abraham F, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin. 1987;13:261–276.
    1. Strauss GP, Gold JM. A psychometric comparison of the clinical assessment interview for negative symptoms and the brief negative symptom scale. Schizophr Bull. 2016;42:1384–1394.
    1. Kring AM, Raquel, Steven P. The clinical assessment interview for negative symptoms (CAINS): Final development and validation. Am J Psychiatry. 2013:165–172.
    1. Velligan DI, Robertt D, Brown M. A randomized pilot study of motivation and enhancement training (MOVE) for negative symptoms. Schizophr Res. 2015;165:175–180.
    1. Daniel DG, Alphs L, Cazorla P. Training for assessment of negative symptoms of schizophrenia across languages and cultures: Comparison of the NSA-16 with the PANSS negative subscale and negative symptom factor. Clin Schizophr Relat Psychoses. 2011;5:87–94.
    1. Daniel DG. Issues in selection of instruments to measure negative symptoms. Schizophr Res. 2013;150:343–345.
    1. Kay SR, Abraham F, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–276.
    1. Andreasen NC. Scale for the assessment of positive symptoms (SAPS) Iowa City: University of Iowa; 1984.

    1. Andreasen NC (2013) Department of psychiatry, University of Iowa college of medicine 52242.

    1. Andreasen NC. Scale for the assessment of negative symptoms (SANS) Iowa City: University of Iowa; 1984.
    1. Kring AM, Gur RE, Blanchard JJ, Horan WP, Reise SP. The clinical assessment interview for negative symptoms (CAINS): Final development and validation. Am J Psychiatry. 2013;170:165–172.
    1. Kirkpatrick B, Strauss GP, Nguyen L, Fischer BA, Daniel DG, et al. The brief negative symptom scale: Psychometric properties. Schizophr Bull. 2011;37:300–305.
    1. Axelrod BN, Goldman RS, Alphs LD. Validation of the 16-item negative symptomassessment. J Psychiatr Res. 1993;27:253–258.
    1. Velligan DI, Alphs L, Lancaster S, Morlock R, Mintz J. Association between changes on the negative symptom assessment scale (NSA-16) and measures of functional outcome in schizophrenia. Psychiatry Res. 2009;169:97–100.
    1. Portilla MPG, Alvarez LG, Saiz PA, Al Halabi S, Bascaran, et al. Psychometric evaluation of the negative syndrome of schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2015;265:559–566.
    1. Alphs L, Morlock R, Coon C, van Willigenburg A, Panagides J. The 4-item negative symptom assessment (NSA-4) instrument: A simple tool for evaluating negative symptoms in schizophrenia following brief training. Psychiatry (Edgemont) 2010;7:26–32.
    1. Alphs L, Morlock R, Coon C, Cazorla P, Szegedi A. Validation of a 4-item Negative Symptom Assessment (NSA-4): A short, practical clinical tool for the assessment of negative symptoms in schizophrenia. International Journal of Methods in Psychiatric Research 2011
    1. Guy W. Clinical global impression In: ECDEU Assessment Manual for Psychopharmacology (revised) Rockville, MD: National Institute of Mental Health; 1976. pp. 217–221.
    1. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the clinical global impression (CGI) scale for use in bipolar illness: The CGI-BP. Psychiatry Res. 1997;73:159–171.
    1. Haro JM, Kamath SA, Ochoa S. The clinical global impression-Schizophrenia scale: A simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand. 2003;107:16–23.
    1. Kay SRF, Opler LA. The positive and negative syndrome Abraham scale (PANSS) for schizophrenia. Schizophrenia Bulletin. 1987;13:261–276.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する